|12th June 2019||Allan L Goldstein||228,000||Bona fide gift||$0.00|
|6th January 2019||Allan L Goldstein||208,912||Conversion of derivative||$0.06||$12,534.72|
|6th January 2019||Joseph C Mcnay||522,280||Conversion of derivative||$0.06||$31,336.80|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.